...of Hope researchers described an oncolytic virus engineered to express a truncated CD19 that enabled anti-CD19... ...B cells 1
University of Chicago
City of Hope
University of Luxembourg
Icahn School of Medicine at Mount Sinai
The earliest clinical efficacy data for TCR2’s mesothelin-targeted TRuC T cell therapy hint that the engineered TCR T cells may work in solid tumors, where CAR T cells have yet to shine. Shares of TCR...
...A Gilead spokesperson told BioCentury the wholesale acquisition cost for a one-time infusion of the CD19-directed... ...Gilead’s Yescarta axicabtagene ciloleucel and Kymriah tisagenlecleucel from Novartis AG (NYSE:NVS; SIX:NOVN), which also target CD19... ...T cell therapy against CD19 (KTE-C19) (FKC-876)
Gilead Sciences Inc.
Kite Pharma Inc.
bluebird bio Inc.
Bristol Myers Squibb Co.
...selectively eliminating alloreactive T and NK cells. A Baylor team reported in Nature Biotechnology that anti-CD19... ...tumor eradication and survival benefit in xenograft mouse models of leukemia and neuroblastoma versus conventional CD19-targeting...